Mutations in the aristaless-related homeobox (ARX) gene result in a spectrum of structural and functional nervous system disorders including lissencephaly, movement disorders, intellectual disabilities, and epilepsy. Some patients also have symptoms indicating hypothalamic dysfunction, but little is known about the role of ARX in diencephalic development. To begin evaluating diencephalic defects, we examined the expression of a panel of known genes and gene products that label specific diencephalic nuclei in 2 different Arx mutant mouse lines at E18.5. Male mice engineered to have a polyalanine expansion mutation (Arx
INTRODUCTION
The aristaless-related homeobox gene, ARX, is an evolutionarily conserved transcription factor found on the X chromosome that is required for normal forebrain development (1Y4). A variety of mutations in this gene have been described in human patients, typically males; these are associated with a diverse array of phenotypes that range from relatively mild intellectual disability, various types of epilepsy, and social impairments to severe structural malformations such as agenesis of the corpus callosum and lissencephaly (3, 4) . Mutations in highly conserved amino acids of the homeodomain, large deletions, and truncations frequently give rise to severe structural abnormalities, intractable seizures, ambiguous genitalia, and death in the neonatal period (1, 5) . In contrast, mutations that result in an expansion of the first polyalanine tract of the gene, such as those found in patients with Ohtahara or West syndrome, typically do not lead to obvious structural changes but do result in infantile spasms or other severe epilepsies, accompanied by intellectual disabilities later in life (6Y8).
Interestingly, patients with X-linked lissencephaly with ambiguous genitalia (XLAG) with loss-of-function mutations as previously described, also present with impaired temperature and circadian rhythm regulation, both of which are referable to hypothalamic dysfunction (9Y11). Although it is known that Arx is expressed as early as E12.5 in the mouse diencephalon, including regions destined to become specific ventral thalamic nuclei and hypothalamic nuclei (1, 12, 13) , its precise role in the patterning and specification of these regions is largely unknown.
In view of the expression of Arx in the anlagen for the hypothalamus and the hypothalamic dysregulation observed in patients, as well as the implicated involvement of the thalamus in several forms of epilepsy, particularly infantile spasms (14, 15) , we hypothesized that Arx has a role in normal diencephalic development and function. To begin testing this hypothesis, we examined the expression of various markers in specific diencephalic nuclei during development using immunohistochemistry and in situ hybridization. Furthermore, we evaluated these nuclei in 2 Arx mutant mouse models. One model includes an expansion of the first polyalanine tract (Arx
). Patients with this mutation often survive past early childhood and typically do not exhibit features of hypothalamic dysregulation, although they do exhibit progressive epilepsy and learning deficits (6, 7, 16) . In contrast, patients with a deletion or loss of function, comparable to our second mouse model (Arx j/Y ), frequently succumb in the perinatal period with evidence of hypothalamic dysregulation. Interestingly, this mouse model and XLAG patients exhibit similar brain morphologic and functional abnormalities. We now report that the hypothalamic nuclei appear intact in both mouse models at E18.5; however, the Arx j/Y mice lack expression of specific markers in the thalamic reticular nucleus (TRN) and zona incerta (ZI). In addition, the A13 subnucleus of the ZI lacks the expected dopaminergic neuronal marker, tyrosine hydroxylase. These findings suggest that although Arx is not required for diencephalic patterning, it is essential for the proper development and specification of discrete sub-populations of neurons in the thalamus.
MATERIALS AND METHODS

Mice
All animal experiments were performed in accordance with the Children's Hospital of Philadelphia Animal Care and Use Committee. Male mice carrying a 7-alanine expansion within the first polyalanine tract of Arx (Arx (GCG)7/Y ) were generated and provided by Dr. K. Kitamura (National Center of Neurology and Psychiatry, Tokyo, Japan) (16) . The Arx j/Y mice were generated from mice carrying a floxed allele (17) by crossing homozygous floxed females with males homozygous for E2a-Cre, which expresses CRE ubiquitously in early embryos, before implantation (No. 003724, Jackson Laboratories, Bar Harbor, ME). The resultant compound heterozygous females, effectively Arx j/X , were backcrossed to wild-type (WT) C57B6 males to eliminate the E2a-Cre. As expected, based on the previously described Arx j/Y mice generated in 2002 by Kitamura et al (1) , Arx j/Y mice died shortly after birth and had visibly smaller brains and abnormal fiber tracts (unpublished data).
Tissue Processing and Microscopy
For all experiments, E18.5 male mice were obtained from crosses between heterozygous females (Arx (GCG)7/X or Arx j/X ) and WT C57B6 males. Pregnant dams were killed, the embryos were removed from the uterus and decapitated in cold HBSS (Gibco, Carlsbad CA), and the heads were fixed in 4% paraformaldehyde in 1Â PBS overnight. Heads were washed in 1Â PBS, cryoprotected in 30% sucrose overnight, and then frozen in embedding medium for cryosectioning. Coronal or sagittal serial sections were cut (16-Km thick) and mounted on positively charged slides such that every eighth section shared a slide. Therefore, all labeling protocols were carried out on adjacent sections with sample sizes ranging from 3 to 7 animals for each genotype and stain/antibody/probe. Genotypes and sexes were determined from tail tissue DNA using established primers and polymerase chain reaction protocols (16, 17) . All photos were taken on a Leica DM6000B microscope equipped with a Leica DFC420 camera (Leica, Buffalo Grove, IL).
In Situ Hybridization
Digoxigenin-labeled RNA probes for Nr5a1, Pomc (kindly provided by Dr. D. Epstein, University of Pennsylvania, Philadelphia, PA), Six3 (kindly provided by Dr. P. Gray, Washington University, St. Louis, MO [18] ), Dlx2 (No. 15537, AddGene, Cambridge, MA), and Gad67 (kindly provided by Dr. N. Tillakaratne, University of California, Los Angeles, Los Angeles, CA) were all generated from pBluescript plasmids with DNA template inserts. Briefly, plasmids were linearized with the appropriate restriction enzyme, cleaned with phenol: chloroform and concentrated, then the RNA probe was labeled and amplified with T7 or T3 polymerase in a 1Â mixture of digoxigenin-labeled dNTPs, RNasin, DTT, and enzyme buffer. The DNA template was digested away with DNaseI, and the probes were concentrated, cleaned, and resuspended in RNase-free water for in situ hybridization.
All slides were postfixed in 4% paraformaldehyde for 10 minutes, washed in 0.1% Tween-20 in 1Â PBS, permeabilized in 0.5% proteinase K, and acetylated in 0.1 mol/L triethanolamine (1.86% triethanolamine, 0.4% 10N NaOH, 0.5% acetic anhydride). Slides were incubated with probe in hybridization solution (50% formamide, 5Â SSC, 2% blocking reagent [No. 11096176001; Roche, Mannheim, Germany], 0.1% Triton, 0.15 CHAPS, 1 mg/mL tRNA from yeast, 5 mmol/L EDTA, 50 Kg/mL heparin) overnight at 65-C in a box humidified with a solution of 50% formamide and 5Â SSC. After incubation in 1Â SSC/50% formamide for 30 minutes at 65-C, slides were treated with RNaseA and placed through a series of washes with SSC and MABT (100 mmol/L maleic acid, 150 mmol/L NaCl, 0.1% Tween-20, pH 7.5). After blocking for 1 hour at room temperature in 2% blocking reagent (Roche, Indianapolis, IN) and 20% goat serum, slides were incubated overnight at 4-C with anti-DIG antibody (1:2500, No. 11093274910; Roche) in 2% blocking reagent and 5% goat serum. Slides were washed with five 1-hour washes in MABT and one 10-minute wash in NTM (100 mmol/L Tris pH 9.5, 100 mmol/L NaCl, 50 mmol/L MgCl 2 ) before developing in the dark overnight with BM Purple (No. 11442074001; Roche) at room temperature. Finally, slides were rinsed with NTM, washed 3Â in 1Â PBS, fixed in paraformaldehyde for 30 minutes, dehydrated, and mounted with Permount.
Immunohistochemistry
Detection of Islet-1 (Isl-1) and tyrosine hydroxylase (TH) expression was carried out using standard immunohistochemical protocols. Briefly, slides were baked at 65-C for 20 minutes and either washed with 1Â PBS for 15 minutes and permeabilized with PBS-T (0.5% Triton X-100 in 1Â PBS) with two 5-minute incubations (for TH) or autoclaved in antigen retrieval solution (No. H3300; Vector Laboratories, Burlingame, CA) for 20 minutes at 105-C (for Isl-1). Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 20 minutes, slides washed twice with PBS-T, and blocked first in MOM blocking reagent (for Isl-1, BMK-2202 kit; Vector Laboratories) and then in 10% normal goat serum in PBS-T for 30 minutes (for both Isl-1 and TH). Slides were then incubated overnight in either mouse anti-Islet-1 (5 mg/mL in 10% goat serum, No. 40.2D6; Developmental Studies Hybridoma Bank, Iowa City, IA) at 4-C or in rabbit anti-TH (1:500 in 1% goat serum, No. AB152; Millipore, Billerica, MA) at room temperature. Slides were washed twice, incubated in biotin-conjugated secondary antibody for 30 minutes, followed by 2 more washes, and then a 30-minute incubation with ABC solution (No. PK-6100; Vector Laboratories). Slides were washed twice more and developed with ImmPACT DAB (No. SK-4105; Vector Laboratories) for 2 minutes in the dark. Slides were then dehydrated and mounted with Permount. To evaluate the role of Arx in the development of the hypothalamus, we used a panel of markers known to express in specific hypothalamic regions and nuclei at E18.5. We began with markers specific for the ventromedial hypothalamus (VMH) and the arcuate nucleus (ARC), which are known to regulate satiety and appetite, respectively (19, 20) . In situ hybridization for Nr5a1, which demarcates the VMH (21), was used to assess the general FIGURE 2. Pomc demarcates the arcuate nucleus (ARC) and pituitary in wild-type (WT) and Arx transgenic mice. Representative E18.5 coronal sections probed with Pomc are shown for WT (left panels), Arx (GCG)7/Y (middle panels), and Arx j/Y (right panels) mice. In the WT images, the approximate outline of the left ARC is illustrated by dotted lines in the top, more rostral section, whereas the anterior and posterior pituitary (aPit and pPit, respectively) is labeled in the bottom, more caudal section. These nuclei are also normally expressing Pomc in the Arx transgenic animals. Scale bar = 200 Hm. morphology and placement of the nucleus; Pomc was used to examine these same characteristics in the ARC (22) . In both the Arx (GCG)7/Y and Arx j/Y mice, Nr5a1 was detected in the expected location of the VMH and at visually similar intensity and morphology to WT controls, suggesting proper development of this nucleus despite altered Arx function (Fig. 1) . Likewise, Pomc expression reliably demarcated the ARC in both transgenic mouse models, as it did in WT, an indication that this nucleus also remains intact (Fig. 2) .
RESULTS
Hypothalamic Nuclei Are Intact in
In addition to the ARC, Pomc is also expressed in the pituitary (23) , which releases hormones in response to signals from various hypothalamic centers. As was observed for the ARC, no differences in expression pattern were detected in the pituitary of either Arx (GCG)7/Y or Arx j/Y mice as compared with WT (Fig. 2) .
We next evaluated the suprachiasmatic nucleus (SCN). This nucleus controls the body's circadian rhythms; XLAG patients have difficulty maintaining sleep/wake cycles (9, 11). We assessed location and morphology of the SCN at E18.5 with Six3 expression because this transcription factor is required for SCN development and remains expressed into adulthood (18) . Similar to our hypothalamic nuclei results for Nr5a1 and Pomc, expression of Six3 was unchanged in the SCN of both Arx (GCG)7/Y and Arx j/Y mice when compared with WT mice (Fig. 3) .
In summary, we detected no difference in the expression of a panel of hypothalamic markers. Because this was not a comprehensive analysis, a subtle phenotype may exist that could have been missed in our analysis. Nonetheless, no obvious phenotype was present. Further studies, including functional studies of the hypothalamus, beyond the scope of this investigation, are certainly warranted in view of the clinical phenotypes observed in the patients.
Arx j/Y Mice Lack Specific Marker Expression in the ZI and TRN
In addition to marking the SCN, Six3 is also expressed in several other diencephalic nuclei at E18.5, including the hypothalamic periventricular nuclei, as well as the thalamic ZI and TRN (24) . Although the SCN and periventricular nucleus of the hypothalamus stained strongly for Six3 in all genotypes examined (Figs. 3, 4) , Arx j/Y mice showed a complete absence of expression in the expected thalamic nuclei and subnuclei (Fig. 4) . Arx (GCG)7/Y mice, however, maintained Six3 expression in all expected hypothalamic and thalamic nuclei.
In view of the lack of expression of Six3 in the TRN, the ZI, and the A13 dopaminergic subnucleus of Z1, we sought to define expression patterns further in this region. We began by examining the expression of Isl-1, a LIM domain transcription factor that is highly expressed in these regions (25) . As with Six3, Isl-1 was detected in the entire ZI and TRN of both WT and Arx (GCG)7/Y mice at E18.5 but was completely absent in Arx j/Y mice (Fig. 4) .
ZI and TRN Are Present in Arx j/Y Mice
To address whether the loss of Six3 and Isl-1 expression in the ZI and TRN was caused by complete loss of these nuclei in Arx j/Y mice, we probed for Gad67, which detects all GABAergic interneurons. Although the ZI contains a variety of different neuron types, inhibitory interneurons account for more than 80% of the ventral ZI (26) , and the TRN consists entirely of GABAergic neurons (27, 28) . As expected, Gad67 was detected in the TRN and ZI (but not the dopaminergic A13 region) of both WT and Arx (GCG)7/Y mice at E18.5. Interestingly, and in contrast to our findings for Six3 and Isl-1, Gad67 was also detected in these regions on Arx j/Y sections (Fig. 5) , although the level of expression appeared slightly reduced, and perhaps restricted, as compared with that in WT mice. Despite this possible decrease, the presence of Gad67 expression clearly indicates that, although the normal gene expression pattern is altered in the ZI and TRN at this age, these nuclei are present and remain GABAergic.
The A13 subnucleus of the ZI contains dopaminergic neurons and not GABAergic neurons; thus, Gad67 does not label this nucleus in WT mice (Fig. 5) . Dlx2, however, is a known regulator of Isl-1 and dopaminergic fate in the developing ventral thalamus, appearing as early as E10-11 and continues to be expressed in the ZI and TRN until at least P0 (29Y31). Dlx2 is also required for Arx expression and may play a role in GABAergic fate specification in other regions of the developing forebrain (32Y34), placing it upstream of any changes in expression that may be caused by Arx deletion. Thus, it is an ideal marker for the presence or absence of the A13 subnucleus of ZI. As expected, Dlx2 was detected in the appropriate regions for all 3 nuclei and subnuclei at E18.5, regardless of genotype, thus confirming the presence of the ZI and TRN in the Arx j/Y mice and demonstrating that the A13 subnucleus exists (Fig. 5) .
Arx Loss of Function Results in Loss of Dopaminergic Neurons in ZI
Because GABAergic neurons were detected in the ZI and TRN of Arx j/Y mice despite loss of Six3 and Isl-1 expression, we then examined whether the dopaminergic neurons of the A13 subnucleus were also conserved. Previous studies have demonstrated a requirement of Dlx2 for the dopaminergic cell fate in the ventral thalamus, such that loss of Dlx2 eliminates expression not only of Isl-1 but also of TH, an enzyme essential to the synthesis of dopamine and frequently used as a marker of dopaminergic neurons (29) . We, therefore, hypothesized that loss of Arx not only results in loss of Six3 and Isl-1 in the A13 subnucleus at E18.5 but also TH expression and, hence, dopaminergic fate. Immunohistochemical staining for TH confirmed this because it was easily detected in the A13 subnucleus of both WT and Arx (GCG)7/Y mice but not Arx j/Y mice (Fig. 6 ). This implies a requirement for Arx in establishing the dopaminergic fate of these A13 neurons.
DISCUSSION
Immunohistochemistry and in situ hybridization were used to assess the role of Arx in diencephalic development by determining specific marker expression patterns in transgenic mouse models at E18.5. Two mouse lines, which model Ohtahara syndrome and XLAG, were used to determine whether alteration of Arx function in the diencephalon could explain phenotypic components of these syndromes. Although we found no obvious changes to the hypothalamic nuclei in either model, mice with a complete loss of Arx function, Arx j/Y , also lost expression of Six3 and Isl-1 in the TRN and ZI, resulting in the loss of dopaminergic fate in the A13 subregion of the ZI. A schematized depiction of the findings is shown in Figure 7 . These results establish a requirement for Arx expression in the dopaminergic lineage of this discrete population of neurons and suggest a possible alteration in cell fate for other regions of the ZI and TRN.
One of our major findings is the loss of dopamine neurons from the A13 subnucleus of the ZI in Arx j/Y mice, as indicated by the absence of TH staining (Fig. 6 ). Because Dlx2 staining was still detected, these findings suggest a role for Arx in dopaminergic fate determination. Although the precise function of this region is still being elucidated, A13 dopaminergic neurons have been shown to both receive and send projections to several regions of the hypothalamus and thalamus and may be important in the regulation of autonomic, endocrine, and motor functions (34, 35) . Altering the function of these neurons would be expected to impact their normal activity, potentially contributing to some of the ''hypothalamic''-attributable symptoms observed in XLAG patients. Similarly, the requirement of Arx for expression of Six3 and Isl-1 in both the TRN and ZI is a novel finding. Like the ZI A13 subnucleus, the precise function of the ZI itself is controversial, although it has wide and varied connections that Representative coronal sections are shown from E18.5 wild-type (WT) (left panels), Arx (GCG)7/Y (middle panels), and Arx j/Y (right panels) that were probed with Gad67 (top panels) or Dlx2 (bottom panels). The approximate boundaries of the TRN, majority of the ZI, and the ZI's A13 subnucleus (A13) are illustrated with dotted lines in all images. Gad67 is expressed in the TRN and majority of ZI, but not the A13 dopaminergic subnucleus of all 3 genotypes, whereas Dlx2 is expressed in all 3 regions for all 3 genotypes. Scale bar = 500 Hm.
suggest a role in integrating sensory input with arousal, attention, postural, or visceral output (36) . The role of the TRN is also ambiguous; however, it is generally considered to be an important ''gate'' that directs cortical attention and has recently been shown to receive connections from the ZI (37, 38) . Therefore, we speculate that the loss of both Isl-1 and Six3 expression in these nuclei has significant consequences. Microarray and promoter-occupancy studies have failed to show any significant alteration in expression or Arx promoter binding of either Isl-1 or Six3; therefore, it is unlikely that these transcription factors are directly regulated by Arx (17, 39, 40) . Furthermore, because both the TRN and ZI nuclei still contained GABAergic neurons in Arx j/Y mice (as evidenced by Gad67 staining), it is difficult to predict the end effect that loss of these transcription factors would have on the functions of these nuclei. However, particular subtypes of GABAergic interneurons have distinct electrical properties and connections, and whether the appropriate interneuron subtype composition remains in the TRN and ZI of Arx j/Y mice is still unknown because expression of subtype-specific markers does not appear until later ages. Considering that the overall expression of Gad67 in these areas appeared reduced in Arx j/Y mice and that similar mouse models exhibit both reduced numbers and mislocalization of specific interneuron subtypes in other brain regions (1) , it is possible that loss of Arx function in these regions has a similar effect. Such alterations to this delicate balance of GABAergic subtypes would presumably lead to functional consequences, which may also contribute to some of the phenotypes observed in XLAG patients.
Dlx1/2 has been shown to be required for specifying dopaminergic fate in the developing ventral thalamus (29) . Detected as early as E10.5, knocking out both Dlx1 and Dlx2 results in loss of expression of Pax6, Isl-1, and TH from the primitive A13 region at E12.5. Because Arx is a direct target of Dlx2 (32, 33) , Pax6 is known to be regulated by Six3 in other areas of the developing forebrain (41) , and TH is thought to be regulated by Isl-1 (42), the loss of Six3, Isl-1, and TH staining from this same region in our Arx j/Y mice at E18.5 is entirely consistent with the findings in Dlx1/2 compound knockouts. Furthermore, because Dlx2 expression was unaltered in the Arx j/Y mice, our findings are the first to demonstrate that Arx is required for Six3 and Isl-1 expression in mice, as well as dopaminergic fate in this region.
Recent studies in zebrafish have revealed a similar role for Arx in establishing dopaminergic cell fate. Studies using morphants of Arx and Isl-1 have indicated that, whereas Isl-1 is required at later stages for terminal differentiation of dopamine neurons, Arx is required for earlier patterning and for the expression of Pax6a, a homolog of the mouse Pax6 (43) . This is consistent with our findings in the mouse, placing Arx upstream of Six3, Isl-1, and TH expression (Fig. 7) . In the zebrafish studies, knockdown of either Arx or Isl-1 resulted in reduced TH staining; however, contrary to our results, neither Isl-1 or Arx expression was altered when the other was knocked down, indicating 2 independent pathways (43). These findings suggest that, although the necessary gene expression patterns for dopaminergic fate in this region are evolutionarily conserved, the precise pathways involved in establishing these patterns differ between species. Further studies in both species will be useful to identify the intermediate players and their respective roles in determining dopaminergic fate.
The role of Arx in telencephalic development has been extensively studied, and the comparison with these data in the thalamus is of interest. Arx has been shown to play a role in the proliferation of cortical (pallial) progenitor cells (1, 3, 44) and the differentiation of these cells, particularly upper cortical layer neurons (44) . Arx seems to have a more complex role in the development of the ventral telencephalon where it is required for the proliferation, migration, and differentiation of cortical interneurons (1, 32, 45, 46) . In addition, it has clear roles in basal ganglia development and cholinergic neuron differentiation, in particular (47) . Thus, the disruptions we see in the thalamus reflect similar roles for Arx in this brain region, although previous reports have not specifically linked Arx to dopaminergic neuron development.
It is worth noting that all expression changes reported here were only observed in the Arx j/Y mice and not in the Arx (GCG)7/Y mice. This is not particularly surprising, considering FIGURE 7 . Schematized summary of marker expression within the thalamic reticular nucleus (TRN) and zona incerta (ZI) of wild-type (WT) and Arx j/Y mice at E18.5. The expected and observed expression patterns within the WT thalamic nuclei are depicted on the left, with the corresponding observed expression pattern for the Arx j/Y mice depicted on the right. Because Dlx2 is upstream of Arx, its expression pattern is unchanged by loss of Arx. In contrast, Six3, Islet-1 (Isl-1), and tyrosine hydroxylase (TH), previously demonstrated to require Dlx2 for expression in these areas, are lost on loss of Arx. This indicates that Arx is also required for their expression but places it downstream of Dlx2 in the cascade. Gad67 expression is essentially unchanged in the Arx j/Y , indicating that Arx is not required for Gad67 expression in these ventral forebrain regions. Drawings are modified, with permission, from Paxinos et al (48) .
our previous data indicating that only a subset of gene targets are misregulated by polyalanine-expanded Arx as compared with the complete loss of function in Arx j/Y mice (46) . Our data are also consistent with observations from patients with polyalanine expansion mutations, who do not exhibit any outward diencephalic dysfunction. Understanding why different mutations result in distinct phenotypes remains an area of active investigation for ARX and other genes. Work from our laboratory has shown that loss of function (deletions) and alanine track expansion mutations result in distinct downstream transcription networks (44) . We expect that a similar developmental mechanism likely governs the alterations we have observed in the TRN and ZI but not in other regions expressing ARX.
In conclusion, our findings are the first to describe a requirement for Arx in the proper specification of the TRN and ZI in mouse. Furthermore, we illustrate for the first time that the dopaminergic fate of the A13 region depends on functional Arx expression. Taken together, these studies provide further evidence for the specificity of functional consequences for specific Arx mutations and suggest another potential mechanism for the hypothalamic dysregulation observed in patients with severe Arx mutations.
